(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/214487 A1

(51) International Patent Classification:
A61K 9/48 (2006.01) *A61P 11/00* (2006.01)
A61K 31/4178 (2006.01)

(21) International Application Number:
PCT/GB2021/050993

(22) International Filing Date:
23 April 2021 (23.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2006074.5 24 April 2020 (24.04.2020) GB

(71) Applicant: **VICORE PHARMA AB** [SE/SE]; Kornhamnstorg 53, SE-111 27 Stockholm (SE).

(72) Inventors: **CAMBER, Ola**; Kornhamnstorg 53, SE-111 27 Stockholm (SE). **JOHANSSON, Christina**; Viktor Rydbergsgatan 33, SE41257 Göteborg (SE).

(74) Agent: **MCNEENEY, Stephen Phillip**; Potter Clarkson, The Belgrave Centre, Talbot Street, Nottingham NG1 5GG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2021/214487 A1

(54) Title: NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION

(57) Abstract: According to the Invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso- butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is Insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.